Prior Opioid Exposure Influences Parents’ Sharing of Their Children’s CYP2D6 Research Results

Abstract

Aim: To determine parents’ use of their children’s CYP2D6 research result. We hypothesized that perceived utility, likelihood of sharing and actual sharing of results would differ between parents with children previously exposed (cases) or unexposed (controls) to opioids. Methods: We returned results by phone (baseline). We surveyed parents about perceived utility and likelihood of sharing their child’s research result at baseline, and actual sharing at 3 and 12 months. Results: Cases were more likely than controls to agree that they (p = 0.022) and the doctors (p = 0.041) could use the results to care for their child, to report higher likelihood of sharing (p = 0.042) and to actually share results with the child’s doctor (p = 0.026). Conclusion: Prior opioid exposure influenced perceived clinical utility and sharing behaviors.

Keywords::

• clinic utility
• CYD2D6
• pediatric
• pharmacogenetics testing
• return of results
• sharing of results

Acknowledgements

The authors would like to thank Nicole Dalessandro for her assistance with interviews.

Financial & competing interests disclosure

This research is part of a single site eMERGE II networkproject initiated and funded by the NIH, NHGRI U01HG006828 (Cincinnati Children’s Hospital Medical Center (CCHMC)/Boston Children’s Hospital, John B. Harley, PI). This study was also supported in part by the Cincinnati Children’s Research Foundation and its Cincinnati Genomic Control Cohort; and the Better Outcomes for Children (BOfC) project, a Cincinnati Children’s Hospital Medical Center (CCHMC) initiative to collect and store remnant clinical samples for research use, which was initiated with funds committed by CCHMC and grant monies awarded to the University of Cincinnati from the State of Ohio to renovate space for a biobank. B McLaughlin’s current affiliation is Ambry Genetics, Aliso Viego, CA 92656-1423, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Additional information

Funding

This research is part of a single site eMERGE II networkproject initiated and funded by the NIH, NHGRI U01HG006828 (Cincinnati Children’s Hospital Medical Center (CCHMC)/Boston Children’s Hospital, John B. Harley, PI). This study was also supported in part by the Cincinnati Children’s Research Foundation and its Cincinnati Genomic Control Cohort; and the Better Outcomes for Children (BOfC) project, a Cincinnati Children’s Hospital Medical Center (CCHMC) initiative to collect and store remnant clinical samples for research use, which was initiated with funds committed by CCHMC and grant monies awarded to the University of Cincinnati from the State of Ohio to renovate space for a biobank. B McLaughlin’s current affiliation is Ambry Genetics, Aliso Viego, CA 92656-1423, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.